Brief: Revive Therapeutics Announces Publication Showing Bucillamine’S Potential Impact On Covid-19 Omicron Variants
09/01/2023 20:38
Jan 9 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS ANNOUNCES PUBLICATION SHOWING BUCILLAMINE’S POTENTIAL
IMPACT
ON COVID-19 OMICRON VARIANTS
* REVIVE THERAPEUTICS LTD - GOAL DATE FOR FDA TO PROVIDE ITS WRITTEN
RESPONSES ON
BUCILLAMINE IS MARCH 7, 2023
Source text for Eikon: ID:nGNX3xWQll
Further company coverage: RVV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure